{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:09:26Z","timestamp":1771884566156,"version":"3.50.1"},"reference-count":25,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2017,3,24]]},"DOI":"10.1080\/14656566.2017.1282459","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T21:20:27Z","timestamp":1484601627000},"page":"535-543","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":28,"title":["A pangenotypic, single tablet regimen of sofosbuvir\/velpatasvir for the treatment of chronic hepatitis C infection"],"prefix":"10.1080","volume":"18","author":[{"given":"Ilan S.","family":"Weisberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,3,24]]},"reference":[{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.009"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis361"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.06.014"},{"key":"CIT0007","doi-asserted-by":"crossref","unstructured":"Cheng G, Tian T, Lee YJ, et al. GS-5816, a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage, and a high resistance barrier. Abstract. European Association for the Study of the Liver (EASL). Amsterdam, Netherlands; April 2013.","DOI":"10.1016\/S0168-8278(13)61192-7"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0261-7"},{"key":"CIT0010","doi-asserted-by":"crossref","unstructured":"Mogalian E, Shen G, Moorehead L, et al. Drug-drug interaction profile of sofosbuvir\/velpatasvir fixed dose combination. European Association for the Study of the Liver (EASL). Barcelona, Spain; April 2016","DOI":"10.1016\/S0168-8278(16)01136-3"},{"key":"CIT0011","doi-asserted-by":"crossref","unstructured":"Mogalian E, Mathias A, Braindard D, et al. The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor in HCV-uninfected subjects with severe renal impairment. Abstract. European Association for the Study of the Liver (EASL). Vienna, Austria; April 2015.","DOI":"10.1016\/S0168-8278(15)30915-6"},{"key":"CIT0012","unstructured":"Mogalian E, German P, Brainard D, et al. Lack of clinically significant pharmacokinetic drug-drug interaction between sofosbuvir and GS5816 in healthy volunteers. Abstract. American Association for the Study of Liver Disease (AASLD). Washington DC, USA; Nov 2013."},{"key":"CIT0013","doi-asserted-by":"crossref","unstructured":"German P, Mathias A, Pang PS, et al. Healthy volunteer first in human evaluation of GS5816 a novel second generation, broad-spectrum NS5A inhibitor with potential for once-daily dosing. Abstract. European Association for the Study of the Liver (EASL). Amsterdam, Netherlands; April 2013.","DOI":"10.1016\/S0168-8278(13)61196-4"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12435"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1000"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1014"},{"key":"CIT0017","doi-asserted-by":"crossref","unstructured":"Asselah T, Charlton M, Feld J, et al. The ASTRAL studies: evaluation of SOF\/GS-5816 single-tablet regimen for the treatment of genotype 1-6 HCV infection. European Association for the Study of the Liver (EASL). Vienna, Austria; April 2015.","DOI":"10.1016\/S0168-8278(15)31511-7"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"CIT0020","doi-asserted-by":"crossref","unstructured":"Hezode C, REau N, Svarovskaia ES, et al. Resistance analysis in 1284 patients with genotype 1-6 HCV infection treated with sofosbuvir\/velpatasvir in the phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 studies. European Association for the Study of the Liver (EASL). Barcelona, Spain; April 2016.","DOI":"10.1016\/S0168-8278(16)00629-2"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"CIT0023","doi-asserted-by":"crossref","unstructured":"Wyles D, Brau N, Kottilil S, et al. Sofosbuvir\/velpastasvir for 12\u00a0weeks in patients coinfected with HCV and HIV-1: the ASTRAL-5 study. European Association for the Study of the Liver (EASL). Barcelona, Spain; April 2016.","DOI":"10.1016\/S0168-8278(16)00129-X"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"CIT0026","doi-asserted-by":"crossref","unstructured":"Welzel TM, Herzer K, Ferenci P, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with severe liver disease: interim results of a multicenter compassionate use program. European Association for the Study of the Liver (EASL). Vienna, Austria; April 2015.","DOI":"10.1016\/S0168-8278(15)30975-2"},{"key":"CIT0027","doi-asserted-by":"crossref","unstructured":"Hezode C, De Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program. European Association for the Study of the Liver (EASL). Vienna, Austria; April 2015.","DOI":"10.1016\/S0168-8278(15)30159-8"},{"key":"CIT0028","author":"Gane E","year":"2016","journal-title":"Gastroenterology"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2017.1282459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T21:25:44Z","timestamp":1658438744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2017.1282459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,24]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,3]]},"published-print":{"date-parts":[[2017,3,24]]}},"alternative-id":["10.1080\/14656566.2017.1282459"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2017.1282459","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}